Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceutical, Inc., 58027 [2017-26507]
Download as PDF
<![CDATA[
58027
Federal Register / Vol. 82, No. 235 / Friday, December 8, 2017 / Notices
throughout and that the above-quota
tariff rate decrease by five percentage
points during each year of the remedy
period. Chairman Schmidtlein and
Commissioner Williamson additionally
recommend an in-quota tariff rate of 20
percent ad valorem, which would
decrease to 18 percent in the second
year of the remedy period and 15
percent in the third year of the period,
in addition to the current rate of duty.
Vice Chairman Johanson and
Commissioner Broadbent do not
recommend an additional in-quota tariff
rate for large residential washers.
The Commissioners also unanimously
recommend that the President impose a
separate TRQ on imports of covered
parts of large residential washers for a
duration of three years. For U.S. imports
of covered parts that exceed 50,000
units, they recommend a tariff rate of 50
percent ad valorem, in addition to the
current rate of duty. They recommend
that the in-quota volume increase by
20,000 units in each year of the remedy
period, and that the above-quota tariff
rate decrease by five percentage points
each year. They do not recommend an
in-quota tariff rate for covered parts.
SUMMARY OF COMMISSIONERS’ RECOMMENDED ACTIONS LARGE RESIDENTIAL WASHERS
Year 1
Year 2
Year 3
Large Residential Washers: TRQ
In-Quota Volume Level ..............................................................
Above-Quota Tariff Rate ............................................................
In-Quota Tariff Rate (Schmidtlein & Williamson) .......................
In-Quota Tariff Rate (Johanson & Broadbent) ...........................
1.2 million units ..............
50% ................................
20% ................................
0% ..................................
1.2 million units ..............
45% ................................
18% ................................
0% ..................................
1.2 million units.
40%.
15%.
0%.
70,000 units ...................
45% ................................
0% ..................................
90,000 units.
40%.
0%.
Covered Parts: TRQ
sradovich on DSK3GMQ082PROD with NOTICES
In-Quota Volume Level ..............................................................
Above-Quota Tariff Rate ............................................................
In-Quota Tariff Rate ...................................................................
Having made negative findings with
respect to imports from Canada and
Mexico under section 311(a) of the
North American Free Trade Agreement
Implementation Act, the Commissioners
recommend that imports from Canada
and Mexico be excluded from the above
TRQs and increased rates of duty. The
Commissioners also recommend that the
above TRQs and increased rates of duty
not apply to imports from Australia,
Colombia, Costa Rica, the Dominican
Republic, El Salvador, Guatemala,
Honduras, Israel, Jordan, Korea,
Nicaragua, Panama, Peru, and
Singapore, or to imports from the
beneficiary countries under the
Caribbean Basin Economic Recovery
Act.
Availability of the public version of
the report. The public version of the
Commission’s report containing the
Commission’s injury determination, its
remedy recommendations, an
explanation of the basis for its injury
determination and remedy
recommendations, and a summary of
the information obtained in the
investigation is contained in Large
Residential Washers, Inv. No. TA–201–
076, USITC Publication 4745, December
2017.
By order of the Commission.
Issued: December 4, 2017.
Katherine M. Hiner,
Supervisory Attorney.
[FR Doc. 2017–26451 Filed 12–7–17; 8:45 am]
BILLING CODE 7020–02–P
VerDate Sep<11>2014
20:38 Dec 07, 2017
Jkt 244001
50,000 units ...................
50% ................................
0% ..................................
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Janssen
Pharmaceutical, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before February 6, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00081
Fmt 4703
Sfmt 9990
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
September 19, 2017, Janssen
Pharmaceutical, Inc., Buildings 1–5 & 7–
14, 1440 Olympic Drive, Athens,
Georgia 30601 applied to be registered
as a bulk manufacturer of the following
basic classes of controlled substances:
Controlled substance
Methylphenidate .......
Oxycodone ................
Hydromorphone ........
Hydrocodone ............
Oripavine ..................
Thebaine ...................
Oxymorphone ...........
Tapentadol ................
Fentanyl ....................
Drug
code
1724
9143
9150
9193
9330
9333
9652
9780
9801
Schedule
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the above-listed controlled substances
in bulk for distribution to its customers.
Dated: November 17, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–26507 Filed 12–7–17; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\08DEN1.SGM
08DEN1
]]>Agencies
[Federal Register Volume 82, Number 235 (Friday, December 8, 2017)]
[Notices]
[Page 58027]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26507]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Janssen
Pharmaceutical, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before February 6, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on
September 19, 2017, Janssen Pharmaceutical, Inc., Buildings 1-5 & 7-14,
1440 Olympic Drive, Athens, Georgia 30601 applied to be registered as a
bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Methylphenidate.................................. 1724 II
Oxycodone........................................ 9143 II
Hydromorphone.................................... 9150 II
Hydrocodone...................................... 9193 II
Oripavine........................................ 9330 II
Thebaine......................................... 9333 II
Oxymorphone...................................... 9652 II
Tapentadol....................................... 9780 II
Fentanyl......................................... 9801 II
------------------------------------------------------------------------
The company plans to manufacture the above-listed controlled
substances in bulk for distribution to its customers.
Dated: November 17, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-26507 Filed 12-7-17; 8:45 am]
BILLING CODE 4410-09-P
